Skip to main content

Table 3 Summary of events

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  AE grade Number (% of AE) Sex, male N Age, mean (range) Ratio ENG: ACVRL1: SMAD4: not known Dose, mg/kg Dose, mg/day, mean (range) Number of patients Mean months of treatment
at AE
BZB 1 5 (15) 2 65 (61–69) 1:3:0:1 5   5 44.8
2 17 (51) 1 60.3 (35–72) 0:9:1:7 5   10 45.6a
3 10 (30) 2 56.9 (54–73) 0:5:0:5 5   5 36.8b
4 0
5 1 (3) 1 67 1:0:0:0 5 1 36
TH 1 8 (21) 5 67 (50–90) 2:5:0:0 75 (25–100) 7 41.5
2 20 (54) 15 64.2 (53–81) 9:6:1:0   98 (50–200) 16 36.8
3 6 (16) 2 65.8 (59–69) 4:2:0:0   75 (50–100) 6 23.5
4 0
5 3 (8) 3 66.3 (62–78) 2:1:0:0 100 (50–200) 3 11.6
  1. Legend: anot available in 7; bnot available in 5